8-K - Cadrenal Therapeutics, Inc. Common Stock | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Cadrenal Therapeutics reported Q4 and FY 2025 financial results with reduced net loss, $4.0 million cash position, and progress on CAD-1005 Phase 3 trial following positive FDA End-of-Phase 2 meeting.

Key Takeaways

1Completed End-of-Phase 2 FDA meeting on March 26, 2026, clarifying Phase 3 registrational path for CAD-1005 in HIT.

2Phase 2 showed >25% absolute reduction in thrombotic events with CAD-1005 vs placebo on standard therapy.

3Q4 2025 R&D expenses $0.7M vs $1.5M in Q4 2024; G&A $2.4M vs $2.7M.

4FY 2025 net loss $13.2M vs $10.7M in 2024; cash $4.0M as of Dec 31, 2025.

5Evaluating financing alternatives to fund Phase 3 CAD-1005 development.

62.3M common shares outstanding as of Dec 31, 2025.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securi

Financial Results

9.01

Financial Statements and Exhibits.** (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: | Exhibit Number | | Exhibit Descri

Exhibits Only

Source Document

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON MARCH 31, 2026